Learning Objectives

After viewing this presentation, the participant should be able to:

• Define compassion fatigue and burnout in the field of fertility nursing and their signs and symptoms
• Discuss ways COVID-19 has worsened this issue
• Assess strategies to manage compassion fatigue in your work environment
• Recognize the unique contribution and critical role played by the IVF nurse and why this issue matters

 top 
 

Target Audience

This activity is intended to educate nurses and nurse practitioners specializing in reproductive medicine and assisted reproductive technologies.

 top 

Requirements for Successful Completion

To successfully complete this activity for CE credit, the participant will:
1. Take the pretest
2. Review the content in the presentation
3. Complete the posttest with a score of at least 3 correct answers
4. Fill out a brief evaluation

Upon completion of the requirements 1 – 4, a CE certificate will be available for download.

Release & Expiration Dates
December 1, 2022 to March 31, 2023.

 top 

Disclosure Information and Off-Label Uses
It is the policy of Letters & Sciences to ensure balance, independence, and scientific rigor in all educational activities/programs. Those who may have the opportunity to influence content of this CNE program (e.g., planners, faculty, authors, reviewers, and others) must disclose all relevant, significant financial relationships with ineligible companies so that the providers may identify and resolve any conflicts of interest prior to the program. Any relevant financial relationships have been mitigated. No relevant financial relationships were identified for any other individuals with the ability to control content of the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of product(s), device(s) or clinical strategies.

Off-label: The participant is advised that one or more sections in this continuing education activity may contain references to devices and/or protocols or clinical strategies that are unlabeled, investigational, or unapproved by the FDA. Healthcare professionals should note that the use of information presented that is outside of current approved labeling is considered experimental and are advised to consult current prescribing information. The faculty is required to disclose any unlabeled, investigational, and/or unapproved uses or therapies that are to be discussed.

Jason A. Barritt, PhD, ELD, HCLD

• Serves as a consultant for: BluePath Solutions (Solutions Market Research, Vitrolife), California Cryobank, Fuji Film, Good Start Genetics, Inc. (Invitae), Irvine Scientific, TMRW (CAP)
• Serves on the advisory board for: Fuji Film, Irvine Scientific
• Is a speaker for California Cryobank
• Will not be discussing or referring to unlabeled/unapproved uses of drugs, devices, products, protocols, or therapeutic strategies

William H. Kutteh, MD, PhD, HCLD

• Has received research grant support from Ferring Pharmaceuticals and Natera
• Has served as a speaker for AbbVie
• Will not be discussing or referring to unlabeled/unapproved uses of drugs, devices, products, protocols, or therapeutic strategies

Carol B. Lesser, MSN, NP-C

• Has no relationships to disclose
• Will not be discussing or referring to unlabeled/unapproved uses of drugs, devices, products, protocols, or therapeutic strategies

Kaylen M. Silverberg, MD

• Has received research grants from Baxter
• Has received consulting fees from Baxter, Seikagaku, Serono
• Has served as a speaker for AbbVie, Myovant
• Is a co-founder and member of board of directors: Ovation Fertility
• Will not be discussing or referring to unlabeled/unapproved uses of drugs, devices, products, protocols, or therapeutic strategies

Hugh S. Taylor, MD

• Has received grant/research support from AbbVie Pharmaceuticals
• Has founders options: DOTLab
• Will not be discussing or referring to unlabeled/unapproved uses of drugs, devices, products, protocols, or therapeutic strategies

Executive Committee, CNE Committee, Planning Committee, Curriculum Committee Members
Letters & Sciences, the content managers/members of the Planning, Executive and Curriculum Committees, report no relationships with ineligible companies.

External Review
In accordance with the policies of Letters & Sciences, and in compliance with the standards of ANCC to identify and resolve any potential conflicts of interest, to assure fair balance, independence and objectivity, and to instill scientific rigor in all accredited activities, all presentations with any potential for conflicts of interest, have been reviewed by external reviewers. The external reviewers, who have no potential conflicts of interest, have determined that no bias exists in these presentations. The external reviewers are:

Shannon L. DeVita, MSN, RN, CNL, DNP
Nurse Practionier
San Diego, California

Michele Nichols, PharmD
Pharmacy Consultant
Private Practice
Raritan, New Jersey
 top 

Accreditation Statements

Continuing Nursing Education with Distinction & Credit Designation
Letters & Sciences is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Each activity has been designated for 0.5 contact hours.

Nonendorsement of Products
The learner is advised that the educational content contained herein was developed by and reflects the opinions of the presenters and faculty, and does not necessarily reflect the opinions or recommendations of the educational provider or the commercial supporter. Accredited status does not imply endorsement by Letters & Sciences or the American Nurses Credentialing Center’s Commission on Accreditation of any commercial product discussed/displayed in conjunction with the educational activity.

 top 

Commercial Support

This program is supported by educational grants from
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Organon
Ferring Pharmaceuticals, Inc.

 top